‼️ #ASCO24 simultaneous publication by Sam Klempner et al: PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity across 28-8, 22C3, and SP263 assays: brnw.ch/21wKljg

#ASCO24 plenary: ESOPEC 👏👏 👉🏼neoadj CROSS vs peri-op FLOT in pts with EAC 👉🏼221 in FLOT vs 217 CROSS arm 👉🏼 Median OS: 66mo FLOT vs 37mo CROSS 👉🏼 3-year OS 57.4% FLOT vs 50.7% (95% CI 43.5 – 57.5%) for CROSS (HR 0.70, 95% CI 0.53-0.92, p=0.012)

The June issue of Cancer Discovery is online! On the cover: Efficacy and Safety of Adagrasib + Cetuximab in Patients w/#KRAS G12C-Mutated Metastatic CRC by Nataliya Uboha Rona Yaeger Sam Klempner Scott Kopetz et al. Plus commentaries for #ASCO24 & much more: aacrjournals.org/cancerdiscover…

I am pleased to inform you that the primary result of JCOG1109 was published in the Lancet today. The neoadjuvant triplet chemotherapy would be the standard care for the locally advanced ESCC. Many thanks to everyone involved. thelancet.com/action/showPdf…

I'd like to call attn. to an outstanding professional development opportunity, the ASCO Leadership Development Program! I served as a Board liaison mentor & can't overemphasize the impact LDP can have on the career trajectory of participants. Apply here: brnw.ch/21wLj31

Congratulations to Harsh Singh and Dana-Farber team for getting this data out. CAPOX + Trastuzumab + Bevacizumab in frontline HER2+ gastroesophageal. Nature Communications James Cleary Ronan Kelly and others rdcu.be/dQvh4 -- full paper doi.org/10.1038/s41467…

Building one of the largest datasets of gastric cancer peritoneal metastases in the world, we unravel new biology of organotropism, the important role of the tumor microenvironment and novel biomarkers. Just published in Gastroenterology! Joseph J Zhao gastrojournal.org/article/S0016-…

Pleased to share final survival results of two phase 3 of zolbetuximab NEJM  which reinforce zolbetuxumab plus chemo as effective treatment option, though still need better treatment. More agents will be coming for CLDN18.2+ GC ESMO - Eur. Oncology OncoAlert #ESMO24 nejm.org/doi/full/10.10…

Great to have another option for patients. Kohei shitara Manish A. Shah ILSON David @FlorianLordick Sara Lonardi and many others. FDA Approves Zolbetuximab Plus Chemo for CLDN18.2+ Gastric or GEJ Adenocarcinoma onclive.com/view/fda-appro… via @onclive

Adding to the ever growing approaches in GEA. Journal of Clinical Oncology ASCO. DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or GEJ Adenocarcinoma: DisTinGuish | ascopubs.org/doi/10.1200/JC…

Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

SCI members Howard Chang, Mischel Lab, and others found that blocking #CHK1 activity leads to death of #ecDNA containing tumor cells and tumor regression in mice with a gastric tumor driven by DNA circles. go.nature.com/3Cy7Blr

Cool paper from Shadi Esfahani and team in Science Translational Medicine Mass General Cancer Center Development of a fibrin-targeted theranostic for gastric cancer | Science Translational Medicine science.org/doi/10.1126/sc…

Proof of principle in KRAS G12C CRC, analogous to EGFR rechallenge in RAS WT Colon cancer. Mass General Cancer Center JCO Precision Oncology Anti-KRAS G12C + Anti-EGFR Rechallenge in Chemotherapy-Refractory KRAS G12C–Mutated Colorectal Cancer. ascopubs.org/doi/10.1200/PO…

Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial aacrjournals.org/clincancerres/… Jeeyun Lee MD Minae An Arnav Mehta Clinical Cancer Research

Attending the #AACR25 session on Innovative Paradigms in Immunotherapy Combos in Gastric Cancer? Read speaker Sam Klempner's recent Cancer Discovery paper: Early Immune Remodeling Steers Clinical Response to Frontline Chemoimmunotherapy in Advanced Gastric Cancer doi.org/10.1158/2159-8…

Enjoying interacting with other speakers and discussants during today’s plenary. Exciting new data was presented.

FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….

Givastomig, a novel claudin 18.2/4-1BB bispecific antibody, in combination with nivolumab and mFOLFOX in mGEC 🔎Phase I/II 👉ORR 71% 🧐 Interesting activity #ESMOAmbassadors #ESMOGI25 ESMO - Eur. Oncology

Examining periop Checkpoint inhibitor benefit in gastro-esophageal cancer... sciencedirect.com/science/articl… Led by very talented Joseph J Zhao and Kennedy Ng. Raghav Sundar